Navigation Links
Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
Date:9/23/2008

otein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, the FDA may not establish specific guidelines for a pathway for the approval of FOB products, FOB products may not be accepted by consumers, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results
'/>"/>

SOURCE Insmed Inc.; Premacure AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Insmed to Present at Biosimilars 2008 Conference
2. Insmed to Present at BioPharm Asia 2008 Conference
3. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
4. Insmed CEO to Present at Drug Discovery & Development Conference
5. Insmed to Host Second Quarter 2008 Conference Call
6. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
7. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
8. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
9. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
10. Insmed Announces First Quarter 2008 Financial Results
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... concerned and troubled about the editorial titled, "End ... last week's Wisconsin State Journal (08/07/03). Wisconsin is only ... this channel of distribution and growing industry. The notion ... just plain bad business. We need to encourage the ...
... Now Largest Venture Capital Firm Based in Wisconsin ... raised and closed an additional round of fund raising ... to support applied technology, life sciences, healthcare and business ... and the Midwest. Milwaukees Baird Venture Partners was picked ...
... Wisconsin Technology Network recently interviewed two University of Wisconsin-Madison researchers ... principles behind learning a game can be used in academics. ... James Gee, Ph.D. , is a professor of Curriculum and ... the author of What Video Games Have to Teach Us ...
Cached Biology Technology:Is Wisconsin a Technology Leader or Laggard? 2Milwaukee Company Raises $90 million VC Fund for Midwest Projects 2Milwaukee Company Raises $90 million VC Fund for Midwest Projects 3The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 2The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 3The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 4The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 5The Learning Game - Researchers Study Video Gaming Principles that Apply to Education 6
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... the October 2011 issue of Experimental Biology and ... Medical Center led by Stephen Tsang, MD, Ph.D have ... model for retinitis pigmentosa (RP) using novel bipartite gene ... by progressive degeneration of rod photoreceptors (which mediate night ...
... Advances in tissue engineering and stem cell therapies ... National Institutes of Health,s fourth Symposium on Cardiovascular Regenerative ... 30 leading researchers will share insights into the state ... sponsored by the NIH,s National Heart, Lung, and Blood ...
... Karolinska Institutet have discovered a new inherited disorder that ... adenosine kinase deficiency, is caused by mutations in the ... The findings, which are presented in the ... possible through the detailed biochemical examination of a Swedish ...
Cached Biology News:Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 2Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa 3NIH hosts Cardiovascular Regenerative Medicine Symposium Oct. 4-5 2New inherited neurometabolic disorder discovered 2